key: cord-0700523-lrkavxn4 authors: Fang, Xiaoyu; Ming, Chao; Cen, Yuan; Lin, Hao; Zhan, Kegang; Yang, Sha; Li, Li; Cao, Guoqiang; Li, Qi; Ma, Xiangyu title: Post-sequelae one year after hospital discharge among older COVID-19 patients: a multi-center prospective cohort study date: 2021-12-10 journal: J Infect DOI: 10.1016/j.jinf.2021.12.005 sha: e635bb028bf9da239551722a96a0e2208ca1a5c7 doc_id: 700523 cord_uid: lrkavxn4 BACKGROUND: : To systematically evaluate the prevalence of post-sequelae and chronic obstructive pulmonary disease assessment test (CAT) scoring one year after hospital discharge among older COVID-19 patients, as well as potential risk factors. METHODS: : A multi-center prospective cohort study involving 1,233 eligible older COVID-19 patients was conducted. All patients were followed-up between Mar 1, 2021 and Mar 20, 2021. CAT scoring was adopted to measure symptom burden in COVID-19 patients. RESULTS: : Of the 1233 eligible cases, 630 (51.1%) reported at least one sequelae. The top six post-sequelae included fatigue (32.4%), sweating (20.0%), chest tightness (15.8%), anxiety (11.4%), myalgia (9.0%), and cough (5.8%). Severe patients had significantly higher percentage of fatigue, sweating, chest tightness, myalgia, and cough (P<0.05), while anxiety was universal in all subjects. Sweating, anxiety, palpitation, edema of lower limbs, smell reduction, and taste change were emerging sequelae. Disease severity during hospitalization (OR: 1.46, 95% CI: 1.15-1.84, P=0.002), and follow-up time (OR: 0.71, 95% CI: 0.50-0.99, P=0.043) were independently associated with risk of post-sequelae, while disease severity during hospitalization was significantly associated with increased risk of emerging sequelae (OR: 1.33, 95% CI: 1.03-1.71, P=0.029). The median of CAT score was 2 (0–5) in all patients, and a total of 120 patients (9.7%) had CAT scores ≥10. Disease severity during hospitalization (OR: 1.81, 95% CI: 1.23-2.67, P=0.003) and age (OR: 1.07, 95% CI: 1.04-1.09, P<0.001) were significantly associated with increased risk of CAT scores ≥10. CONCLUSIONS: : While the dramatic decline in the prevalence rate of persistent symptoms is reassuring, new sequelae among older COVID-19 patients cannot be ignored. Disease severity during hospitalization, age, and follow-up time contributed to the risk of post-sequelae and CAT scoring one year after hospital discharge among older COVID-19 patients. Our study provides valuable clues for long-term post-sequelae of the older COVID-19 patients, as well as their risk factors. cough dropped significantly, but still cannot be ignored. 2. New sequelae among older COVID-19 patients require adequate attention and appropriate intervention. 3. Disease severity during hospitalization, age, and follow-up time contributed significantly to the risk of post-sequelae and CAT scoring one year after hospital discharge among older COVID-19 patients. To systematically evaluate the prevalence of post-sequelae and chronic obstructive pulmonary disease assessment test (CAT) scoring one year after hospital discharge among older COVID-19 patients, as well as potential risk factors. A multi-center prospective cohort study involving 1,233 eligible older COVID-19 patients was conducted. All patients were followed-up between Mar 1, 2021 and Mar 20, 2021. CAT scoring was adopted to measure symptom burden in COVID-19 patients. Of the 1233 eligible cases, 630 (51.1%) reported at least one sequelae. The top six postsequelae included fatigue (32.4%), sweating (20.0%), chest tightness (15.8%), anxiety (11.4%), myalgia (9.0%), and cough (5.8%). Severe patients had significantly higher percentage of fatigue, sweating, chest tightness, myalgia, and cough (P<0.05), while anxiety was universal in all subjects. Sweating, anxiety, palpitation, edema of lower limbs, smell reduction, and taste change were emerging sequelae. Disease severity during hospitalization (OR: 1.46, 95% CI: 1.15-1.84, P=0.002), and follow-up time (OR: 0.71, 95% CI: 0.50-0.99, Coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to pose a global threat. 1 As of August, 2021, it has caused more than 109 million confirmed cases with more than 4.4 million deaths worldwide. 2 The coronavirus (including severe acute respiratory syndrome [SARS] and Middle East respiratory syndrome [MERS] ) pandemic has caused long-term pulmonary, cardiovascular, neuropsychiatric and systemic sequelae in the affected patients. 3, 4 Continued attention to global proliferation needs to be accompanied by systematic research on the long-term sequelae of COVID-19 recovery to establish an evidence-based system of prognostic assessment and health promotion. 5 Both the occurrence and prognosis of COVID-19 were closely related to older age. [6] [7] [8] To date, series of studies have reported the potential short-to long-term sequelae of COVID-19 recovery, ranging from two months to one year. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] However, the older patients have not attracted enough attention and no specific studies quantified the temporal trends and associated risk factors for sequelae of COVID-19 in older patients, especially long-term sequelae. In addition, although there were currently no agreed measures to assess the pulmonary burden of COVID-19, chronic obstructive pulmonary disease (COPD) assessment test (CAT), an eight-item questionnaire designed to quantify health status impairment in COPD patients, was adopted to measure pulmonary burden in COVID-19 patients and recognized by the scientific community. 26 Here we systematically evaluated the post-sequelae one year after hospital discharge among older COVID-19 patients in a multi-center prospective cohort study, we also explored the risk factors of post-sequelae and CAT scoring one year after hospital discharge among older COVID-19 patients. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline was implemented to enhance the reporting quality of this manuscript. Totally included in this multi-center prospective cohort study were real-time reverse transcription polymerase chain reaction (RT-PCR)-confirmed older COVID-19 patients (age ≥ 60) who were discharged from Huoshenshan Hospital and Taikang-Tongji Hospital (both in Wuhan, China) between Feb 12 and Apr 10, 2020. 8 All discharged patients met the uniform discharge criteria of the World Health Organization interim guidance. 27 The follow-up was conducted between Mar 1, 2021 and Mar 20, 2021. Exclusion criteria included (1) participants who refused, (2) those who could not be contacted, and (3) those who died before the follow-up visit. This study was approved by the Daping Hospital of Army Medical University (Ethics number 202153). Verbal informed consent was obtained from all patients or their legal guardians prior to the survey due to the telephone follow-up. The disease severity during hospitalization was defined by World Health Organization (WHO) guideline for COVID-19. 28 The severe refers to fever or suspected respiratory infection, plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2 ≤ 93% on room air. 28 Fever was defined as an axillary temperature of 37.3°C or higher. The baseline characteristics, including demographic characteristics, coexisting disorders, and the clinical symptoms, were extracted from the electronic medical records using a uniformed questionnaire by two trained physicians, and validated by a telephone-interview. The one-year follow up was conducted via telephone interview by trained physicians using a uniformed questionnaire including self-reported symptoms, and CAT score items, of which ≥ 10 (the threshold for maintenance treatment in COPD) and >2 (the median value) were treated as categorical outcomes. Patients were asked to report any sustained, intermittent, and emerging symptoms, respectively. The patient's current symptoms were carefully documented and evaluated by specialists to distinguish from their pre-disease status or other underlying diseases that were not associated with COVID-19. All survey data was double entered and validated using EpiData (version 3.1, EpiData Association, Odense, Denmark) software, and disputes were arbitrated by the expert committees composed of experts of respiratory and critical care medicine, and epidemiology. Categorical variables were described using frequency rates and percentages, while continuous variables were described using the median/interquartile range (IQR) values. Categorical variables were compared using the chi-squared test or fisher's exact test as appropriate, while continuous variables were compared using Manne-Whitney U test. The missing values of all potential predictors (missing rate of less than 5.0%) were imputed by expectationmaximization (EM) method. To test for the risk of bias due to the patients who were lost to follow-up, 1:1 propensity score-matching (PSM) between the lost to follow-up subpopulation and the enrolled subpopulation was carried out. Univariate logistic regression analysis was used to screen the potential risk factors which reached a P value of less than 0.1, and calculate their odds ratios (ORs) and corresponding confidence intervals (CIs). Then, the independent risk factors were derived from a stepdown selection process in multivariate logistic regression model. Multivariable adjusted logistic regression analysis was then used for exploring independent risk factors associated with any post-sequelae, CAT scores ≥10 or >2 (the median value). All statistical analyses were conducted using the R software version 4.0.0 (Institute for Statistics and Mathematics, Vienna, Austria). The reported statistical significance levels were all 2-sided, and a level of < 0.05 was considered statistically significant. Figure 1 presented the flow chart of the inclusion procedure of the older COVID-19 patients. Totally 2242 COVID-19 patients with age ≥ 60 were admitted to these two hospitals, and 87 and short of breath (45.2%). Compared with non-severe cases, the severe were elder, more likely to be male, had more coexisting disorders, clinical symptoms, and receive more treatments. Table 2 presented the post-sequelae and CAT scoring one year after hospital discharge, including systemic/general sequelae (34.6%), neurological sequelae (29.0%), cardiovascular sequelae (19.0%), respiratory sequelae (10.1%), and digestive system sequelae (1.9%). Of the 1233 eligible cases, 630 patients (51.1%) reported at least one sequelae at follow up, and the severe group had significantly higher percentage than the non-severe group (57.5% vs 47.5%, P=0.001). The top six post-sequelae included fatigue (32.4%), sweating (20.0%), chest tightness (15.8%), anxiety (11.4%), myalgia (9.0%), and cough (5.8%). Severe patients had significantly higher percentage of fatigue, sweating, chest tightness, myalgia, and cough (P<0.05), while anxiety was universal in all subjects. Of them, fatigue, chest tightness, myalgia, and cough were sustained symptoms, although the prevalence rate dropped sharply ( Figure 2) . Sweating, anxiety, palpitation, edema of lower limbs, smell reduction, and taste change were emerging sequelae ( Figure 2 ). The median of CAT score was 2 (0-5) in all patients, and the severe group had a significantly higher CAT score (3, IQR: 1-6) than the non-severe group (2, IQR: 0-5, p<0.001) ( Table 2 ). A total of 120 patients (9.7%) had CAT scores ≥10, and 597 patients (48.4%) had CAT scores >2. The severe group had significantly higher proportion of patients with CAT score both ≥10 and >2 than the non-severe group (P<0.001). As the patients lost to follow-up before were a little older than those enrolled (Supplementary Table 1 ), PSM was conducted to evaluate the lost to follow-up bias in the sensitivity analysis. Totally 843 patients in the enrolled population were matched successfully with those lost to follow-up, and the baseline characteristics were comparable (Supplementary Table 1 ). We then compared the post-sequelae one year after hospital discharge between totally enrolled patients (n=1233) and those selected by PSM (n=843) (Supplementary Table 2 (Table 3-4, and Supplementary Table 3 (Table 3) . Table 4 Table 7 -8) . Risk factors for CAT scoring one year after hospital discharge were also evaluated for all older COVID-19 patients ( inversely associated with increased risk of CAT scores >2 (Table 6 ). Age was an independent risk factor for the occurrence and prognosis of COVID-19, and older COVID-19 patients need more health monitoring and medical promotion. In the current study, we systematically evaluated the prevalence rate of post-sequelae and CAT scoring one year after hospital discharge among older COVID-19 patients, as well as the potential risk factors in a multi-center prospective cohort study. We revealed that more than half of the patients reported at least one sequelae one year after hospital discharge, and disease severity during hospitalization was independently associated with increased risk of post-sequelae and emerging sequelae. Totally 9.7% of patients had CAT scores ≥10, and 48.4% had CAT scores >2. Disease severity during hospitalization and age significantly associated with increased risk of CAT scores ≥10. Age was significantly associated with increased risk of CAT scores >2, while follow-up time was inversely associated with increased risk of CAT scores >2. To our knowledge, this should be the first study to focus on long-term postsequelae of the older COVID-19 patients, as well as their risk factors. Scientific and clinical evidence was evolving regarding the subacute and long-term effects of COVID-19, which may be caused by cellular damage, innate immune response and procoagulant state caused by SARS-CoV-2 infection. 29, 30 A systematic review reported that the median proportion of individuals experiencing at least one short-term persistent symptom was 72.5% (IQR: 55.0%-80.0%), which was higher than 51.1% in our study. 31 However, we didn't find significant difference between several medium-term reports and our results. 9, 12, 13, 15, 32 Consistent with previous studies, fatigue, which was common after acute lung injury and associated with severe impairment of physical function and quality of life, was the most common symptom. 33 Further, the emerging sequelae, including sweating, anxiety, palpitation, edema of lower limbs, smell reduction, and taste change, were all psychological responses and associated with posttraumatic stress disorder (PTSD). [34] [35] [36] In our results, anxiety was universal in all subjects, no matter the severe or the non-severe. This indicated that the psychological comfort after hospital discharge of COVID-19 should not be neglected. As SARS-CoV-2 is an emerging virus, no effective treatment has yet been developed. Corticosteroids, which may reduce inflammatory-induced lung injury, were used frequently for the treatment of viral infections, since high amount of cytokines can be induced by SARS-CoV, 37 MERS-CoV 38 and SARS-CoV-2 infections. 39 However, clinical evidence reveals that corticosteroids cause decreased clearance of SARS-CoV and MERS-CoV and increased complications among survivors. 40 In the recovery trial, the authors identified that dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support. 41 Except for dexamethasone helping benefit patients during hospitalization, however, the conclusion above also reveals that use of steroids should be more precise. Here, our results indicated that usage of corticosteroid-related therapy was associated with increased risk of both post-sequelae and emerging sequelae, although this might be biased by the disease severity during hospitalization, detailed dose and duration information, and selfreporting symptoms. Taking evidence above together, we next should establish more precise guidelines of corticosteroids use, and strike a balance between saving patients' lives during hospitalization and long-term sequelae. The strength of the current study includes the large sample size, detailed questionnaire on sequelae and use of CAT scoring system, long-term follow-up period, and focus on the older population. However, the interpretation and generalizability of the findings in the current study were also affected by several limitations. First, similar to other follow-up studies, high rate of lost follow-up possibly caused by individual willingness of patients not to be continuously concerned might lead to underestimation of the incidence of post-sequelae. However, the PSM suggests this bias might be limited. Second, telephone follow-up relied on patient self-reported symptoms may affect the accuracy of the post-sequelae survey and CAT scoring, although we performed rigorous quality control and repeat surveys of partial samples. Third, the absence of a non-COVID-19 control group and the absence of a pre-COVID-19 CAT assessment of the same patients limited the possibility of a comparative study. Fourth, currently the disease severity during hospitalization was defined by World Health Organization (WHO) interim guideline for COVID- 19 . Further more precise severity markers are warranted to classify the patients and guide precise treatment. Our study provides valuable clues for long-term post-sequelae of the older COVID-19 patients, as well as their risk factors. While the dramatic decline in the prevalence rate of persistent symptoms is reassuring, new sequelae cannot be ignored. Disease severity during hospitalization, age, and follow-up time contributed to the risk of long-term post-sequelae. Studies among different population and exploring relevant mechanisms are warranted to validate the results and popularize our findings. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis Taking pandemic sequelae seriously: from the Russian influenza to COVID-19 long-haulers Long-term consequences of COVID-19: research needs Covid-19 and Immunity in Aging Populations -A New Research Agenda Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis Development and validation of a prognostic nomogram for predicting in-hospital mortality of COVID-19: a multicenter retrospective cohort study of 4086 cases in China Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19 High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19 Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clinical microbiology and infection : the official publication of the Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clinical microbiology and infection : the official publication of the Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clinical microbiology and infection : the official publication of the European Society of Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19 Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study Analysis of clinical symptoms, radiological changes and pulmonary function data 4 months after COVID-19 Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study lung function and CT findings 3 months after hospital admission for COVID-19 Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. The European respiratory journal Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. The Lancet COPD assessment test for the evaluation of COVID-19 symptoms Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance Clinical management of severe acute respiratory infection ( SARI) when COVID-19 disease is suspected: interim guidance Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls Post-acute COVID-19 syndrome Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review Half-year follow-up of patients recovering from severe COVID-19: Analysis of symptoms and their risk factors Physical complications in acute lung injury survivors: a two-year longitudinal prospective study The STRS (shortness of breath, tremulousness, racing heart, and sweating): A brief checklist for acute distress with panic-like autonomic indicators; development and factor structure Nocturnal Olfactory Stimulation for Improvement of Sleep Quality in Patients With Posttraumatic Stress Disorder: A Randomized Exploratory Intervention Trial Neurophysiological Response to Olfactory Stimuli in Combat Veterans With Posttraumatic Stress Disorder Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoVinfected rhesus macaques Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Dexamethasone in Hospitalized Patients with Covid-19 Li Li). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare that they have no conflicts of interest.